PMID- 17132253
OWN - NLM
STAT- MEDLINE
DCOM- 20061214
LR  - 20190513
IS  - 0146-4760 (Print)
IS  - 0146-4760 (Linking)
VI  - 30
IP  - 8
DP  - 2006 Oct
TI  - Selection and optimization of hydrolysis conditions for the quantification of 
      urinary metabolites of MDMA.
PG  - 563-9
AB  - Recovery of 3,4-methylenedioxymethamphetamine (MDMA) urinary metabolites requires 
      optimization of the hydrolysis of 4-hydroxy-3-methyoxymethamphetamine (HMMA), 
      4-hydroxy-3-methoxyamphetamine (HMA), and 3,4-methylenedioxyamphetamine (MDA) 
      conjugates prior to chromatographic analysis. Acidic and enzymatic hydrolysis 
      with beta-glucuronidase from Escherichia coli and Helix pomatia were evaluated. 
      Acid hydrolysis yielded 40.0% and 39.3% higher HMA recovery compared to E. coli 
      and H. pomatia hydrolysis, respectively (SE=9.8 and 11.4%). E. coli 
      beta-glucuronidase hydrolysis MDA recovery was 17.1% and 26.5% greater than acid 
      hydrolysis and H. pomatia beta-glucuronidase recovery (SE=3.3 and 6.1%), 
      respectively. HMMA recovery by acid hydrolysis was 336.1% and 159.8% greater than 
      E. coli and H. pomatia beta-glucuronidase (SE=72.8 and 31.6%), respectively. The 
      effects of temperature, time, and acid amount on metabolite recovery were also 
      evaluated. HMA and HMMA acid hydrolysis recoveries were improved at 100 degrees C 
      and above. Effective hydrolysis could be conducted in a dry block heater, GC 
      oven, or autoclave at temperatures from 100 to 140 degrees C. Optimal hydrolysis 
      conditions for the measurement of MDMA metabolite conjugates were addition of 100 
      microL of hydrochloric acid to 1 mL urine and incubation at 120 degrees C in a GC 
      oven for 40 min. Therefore, based on HMMA, HMA, and MDA recoveries, time 
      efficiency, availability of instrumentation, and cost, acid hydrolysis was 
      preferred to enzyme hydrolysis.
FAU - Pirnay, Stephane O
AU  - Pirnay SO
AD  - Chemistry and Drug Metabolism, Intramural Research Program, National Institute on 
      Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, 
      Maryland 21224, USA.
FAU - Abraham, Tsadik T
AU  - Abraham TT
FAU - Lowe, Ross H
AU  - Lowe RH
FAU - Huestis, Marilyn A
AU  - Huestis MA
LA  - eng
GR  - Intramural NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PL  - England
TA  - J Anal Toxicol
JT  - Journal of analytical toxicology
JID - 7705085
RN  - 0 (Hallucinogens)
RN  - 117652-28-5 (4-hydroxy-3-methoxymethamphetamine)
RN  - 13026-44-3 (3-O-methyl-alpha-methyldopamine)
RN  - 44RAL3456C (Methamphetamine)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - EC 3.2.1.31 (Glucuronidase)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - QTT17582CB (Hydrochloric Acid)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/chemistry/urine
MH  - Dopamine/analogs & derivatives/chemistry/urine
MH  - Forensic Toxicology/*methods
MH  - Glucuronidase/chemistry
MH  - Hallucinogens/*chemistry/urine
MH  - Humans
MH  - Hydrochloric Acid/chemistry
MH  - Hydrolysis
MH  - Methamphetamine/analogs & derivatives/chemistry/urine
MH  - N-Methyl-3,4-methylenedioxyamphetamine/analogs & derivatives/*chemistry/urine
MH  - Substance Abuse Detection/*methods
EDAT- 2006/11/30 09:00
MHDA- 2006/12/15 09:00
CRDT- 2006/11/30 09:00
PHST- 2006/11/30 09:00 [pubmed]
PHST- 2006/12/15 09:00 [medline]
PHST- 2006/11/30 09:00 [entrez]
AID - 10.1093/jat/30.8.563 [doi]
PST - ppublish
SO  - J Anal Toxicol. 2006 Oct;30(8):563-9. doi: 10.1093/jat/30.8.563.